Bladder Cancer - Results from #10220

REVIEW UroToday

The importance of pelvic lymph node dissection in the elderly population: Implications for interpreting the 2010 National Comprehensive Cancer Network practice guidelines for bladder cancer treatment - Abstract May 9, 2011

Bacillus Calmette-Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer - Abstract May 7, 2011

Lower risk in parous women suggests hormonal factors important in bladder cancer etiology - Abstract May 6, 2011

Gemcitabine for unresectable, locally advanced or metastatic bladder cancer - Abstract May 5, 2011

Experience with ureteroenteric strictures after radical cystectomy and diversion: Open surgical revision - Abstract May 5, 2011

Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer - Abstract May 4, 2011

Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab - Abstract May 3, 2011

Regulation of connexin 43 by basic fibroblast growth factor in the bladder: Transcriptional and behavioral implications - Abstract May 3, 2011

A six-week course of bacillus Calmette-Guérin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53 - Abstract May 2, 2011

Diagnostic test for bladder cancer: The NMP22(®) - Abstract April 29, 2011

Validation of the IMMIDIET food frequency questionnaire in an adult Belgian population: A report from the Belgian case-control study on bladder cancer risk - Abstract April 29, 2011

EAU 2011 - Long term results of the International phase III trial BA06 (MRC) 30894 (EORTC) assessing neo-adjuvant CMV chemotherapy for muscle-invasive bladder cancer - Session Highlights April 29, 2011

Clinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer - Abstract April 28, 2011

Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort - Abstract April 27, 2011

EAU 2011 - Prediction of locally advanced bladder cancer before cystectomy and outcome assessment of patients with bladder cancer after cystectomy using artificial neural networks - Session Highlights April 27, 2011

EAU 2011 - A prospective randomized trial of hexylaminolevulinate (Hexvix) assisted transurethral resection (TURBT) plus single shot intravesical mitomycin (MMC) versus conventional white light TURBT plus single shot MMC in newly presenting bladder cancer April 27, 2011

Radical cystectomy for the treatment of T1 bladder cancer: The Canadian Bladder Cancer Network experience - Abstract April 25, 2011

Urovysion: Considerations on modifying current evaluation scheme, including immunophenotypic targeting and locally set, statistically derived diagnostic criteria - Abstract April 22, 2011

Partial cystectomy: Is it a reliable option for the treatment of bladder leiomyosarcoma? - Abstract April 22, 2011

Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer - Abstract April 21, 2011

Page 512 of 517